Szwed H, Hradec J, Préda I
National Institute of Cardiology, Warsaw, Poland.
Coron Artery Dis. 2001 Feb;12 Suppl 1:S25-8.
Several clinical studies have compared the anti-ischaemic properties of trimetazidine used as monotherapy with those of standard anti-anginal therapy. In the treatment of uncontrolled angina pectoris, the addition of a metabolic agent such as trimetazidine to existing therapy with a haemodynamic agent would appear to confer advantages over the addition of a second haemodynamic agent. Here we report the results of three studies conducted in Poland, the Czech Republic and Hungary that provide additional evidence for the beneficial effects of combining trimetazidine with a conventional haemodynamic agent such as beta-blockers, long-acting nitrate or calcium channel blockers. This combination provided significant benefits in terms of improved exercise capacity and decreased number of angina attacks along with a good tolerability profile.
多项临床研究已将曲美他嗪单药治疗的抗缺血特性与标准抗心绞痛疗法的抗缺血特性进行了比较。在治疗未控制的心绞痛时，在现有的血流动力学药物治疗基础上加用一种代谢药物（如曲美他嗪）似乎比加用第二种血流动力学药物更具优势。在此，我们报告在波兰、捷克共和国和匈牙利进行的三项研究结果，这些研究为曲美他嗪与传统血流动力学药物（如β受体阻滞剂、长效硝酸盐或钙通道阻滞剂）联合使用的有益效果提供了更多证据。这种联合用药在提高运动能力、减少心绞痛发作次数以及具有良好的耐受性方面带来了显著益处。
